Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Rating Increased to Hold at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) to a hold rating in a research report report published on Monday, Zacks.com reports.

Recordati Industria Chimica e Farmaceutica Stock Performance

RCDTF opened at $52.25 on Monday. The business has a 50 day simple moving average of $52.22 and a two-hundred day simple moving average of $51.82. Recordati Industria Chimica e Farmaceutica has a one year low of $52.25 and a one year high of $52.25. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of 18.80 and a beta of 0.33. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%. The firm had revenue of $622.00 million for the quarter.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.